Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition)

Lary A. Robinson, John C. Ruckdeschel, Henry Wagner Jr., Craig W. Stevens

Research output: Contribution to journalArticle

298 Citations (Scopus)

Abstract

Study objectives: Stage IIIA non-small cell lung cancer represents a relatively heterogeneous group of patients with metastatic disease to the ipsilateral mediastinal (N2) lymph nodes and also includes T3N1 patients. Presentations of disease range from apparently resectable tumors with occult microscopic nodal metastases to unresectable, bulky ultistation nodal disease. This review explores the published clinical trials to make treatment recommendations in this controversial subset of lung cancer. Design, setting, and participants: Systematic searches were made of MEDLINE, HealthStar, and Cochrane Library databases up to May 2006, focusing primarily on randomized trials, with inclusion of selected metaanalyses, practice guidelines, and reviews. Study designs and results are summarized in evidence tables. Measurement and results: The evidence derived from the literature now appears to support routine adjuvant chemotherapy after complete resection of stage IIIA lung cancer encountered unexpectedly at surgery. However, using neoadjuvant therapy followed by surgery for known stage IIIA lung cancer as a routine therapeutic option is not supported by current published randomized trials. Combination chemoradiotherapy, especially delivered concurrently, is still the preferred treatment for prospectively recognized stage IIIA lung cancer with all degrees of mediastinal lymph node involvement. Current and future trials may modify these recommendations. Conclusions: Multimodality therapy of some type appears to be preferable in all subsets of stage IIIA patients. However, because of the relative lack of consistent randomized trial data in this subset, the following evidence-based treatment guidelines lack compelling evidence in most scenarios.

Original languageEnglish (US)
Pages (from-to)243S-265S
JournalCHEST
Volume132
Issue number3 SUPPL.
DOIs
StatePublished - Jan 1 2007

Fingerprint

Evidence-Based Practice
Practice Guidelines
Non-Small Cell Lung Carcinoma
Lung Neoplasms
Lymph Nodes
Therapeutics
Neoadjuvant Therapy
Chemoradiotherapy
Adjuvant Chemotherapy
MEDLINE
Libraries
Clinical Trials
Databases
Guidelines
Neoplasm Metastasis
Neoplasms

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Robinson, Lary A. ; Ruckdeschel, John C. ; Wagner Jr., Henry ; Stevens, Craig W. / Treatment of non-small cell lung cancer-stage IIIA : ACCP evidence-based clinical practice guidelines (2nd edition). In: CHEST. 2007 ; Vol. 132, No. 3 SUPPL. pp. 243S-265S.
@article{61ddc92e30b344a8bad96de9fc5b34ce,
title = "Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition)",
abstract = "Study objectives: Stage IIIA non-small cell lung cancer represents a relatively heterogeneous group of patients with metastatic disease to the ipsilateral mediastinal (N2) lymph nodes and also includes T3N1 patients. Presentations of disease range from apparently resectable tumors with occult microscopic nodal metastases to unresectable, bulky ultistation nodal disease. This review explores the published clinical trials to make treatment recommendations in this controversial subset of lung cancer. Design, setting, and participants: Systematic searches were made of MEDLINE, HealthStar, and Cochrane Library databases up to May 2006, focusing primarily on randomized trials, with inclusion of selected metaanalyses, practice guidelines, and reviews. Study designs and results are summarized in evidence tables. Measurement and results: The evidence derived from the literature now appears to support routine adjuvant chemotherapy after complete resection of stage IIIA lung cancer encountered unexpectedly at surgery. However, using neoadjuvant therapy followed by surgery for known stage IIIA lung cancer as a routine therapeutic option is not supported by current published randomized trials. Combination chemoradiotherapy, especially delivered concurrently, is still the preferred treatment for prospectively recognized stage IIIA lung cancer with all degrees of mediastinal lymph node involvement. Current and future trials may modify these recommendations. Conclusions: Multimodality therapy of some type appears to be preferable in all subsets of stage IIIA patients. However, because of the relative lack of consistent randomized trial data in this subset, the following evidence-based treatment guidelines lack compelling evidence in most scenarios.",
author = "Robinson, {Lary A.} and Ruckdeschel, {John C.} and {Wagner Jr.}, Henry and Stevens, {Craig W.}",
year = "2007",
month = "1",
day = "1",
doi = "10.1378/chest.07-1379",
language = "English (US)",
volume = "132",
pages = "243S--265S",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "3 SUPPL.",

}

Treatment of non-small cell lung cancer-stage IIIA : ACCP evidence-based clinical practice guidelines (2nd edition). / Robinson, Lary A.; Ruckdeschel, John C.; Wagner Jr., Henry; Stevens, Craig W.

In: CHEST, Vol. 132, No. 3 SUPPL., 01.01.2007, p. 243S-265S.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Treatment of non-small cell lung cancer-stage IIIA

T2 - ACCP evidence-based clinical practice guidelines (2nd edition)

AU - Robinson, Lary A.

AU - Ruckdeschel, John C.

AU - Wagner Jr., Henry

AU - Stevens, Craig W.

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Study objectives: Stage IIIA non-small cell lung cancer represents a relatively heterogeneous group of patients with metastatic disease to the ipsilateral mediastinal (N2) lymph nodes and also includes T3N1 patients. Presentations of disease range from apparently resectable tumors with occult microscopic nodal metastases to unresectable, bulky ultistation nodal disease. This review explores the published clinical trials to make treatment recommendations in this controversial subset of lung cancer. Design, setting, and participants: Systematic searches were made of MEDLINE, HealthStar, and Cochrane Library databases up to May 2006, focusing primarily on randomized trials, with inclusion of selected metaanalyses, practice guidelines, and reviews. Study designs and results are summarized in evidence tables. Measurement and results: The evidence derived from the literature now appears to support routine adjuvant chemotherapy after complete resection of stage IIIA lung cancer encountered unexpectedly at surgery. However, using neoadjuvant therapy followed by surgery for known stage IIIA lung cancer as a routine therapeutic option is not supported by current published randomized trials. Combination chemoradiotherapy, especially delivered concurrently, is still the preferred treatment for prospectively recognized stage IIIA lung cancer with all degrees of mediastinal lymph node involvement. Current and future trials may modify these recommendations. Conclusions: Multimodality therapy of some type appears to be preferable in all subsets of stage IIIA patients. However, because of the relative lack of consistent randomized trial data in this subset, the following evidence-based treatment guidelines lack compelling evidence in most scenarios.

AB - Study objectives: Stage IIIA non-small cell lung cancer represents a relatively heterogeneous group of patients with metastatic disease to the ipsilateral mediastinal (N2) lymph nodes and also includes T3N1 patients. Presentations of disease range from apparently resectable tumors with occult microscopic nodal metastases to unresectable, bulky ultistation nodal disease. This review explores the published clinical trials to make treatment recommendations in this controversial subset of lung cancer. Design, setting, and participants: Systematic searches were made of MEDLINE, HealthStar, and Cochrane Library databases up to May 2006, focusing primarily on randomized trials, with inclusion of selected metaanalyses, practice guidelines, and reviews. Study designs and results are summarized in evidence tables. Measurement and results: The evidence derived from the literature now appears to support routine adjuvant chemotherapy after complete resection of stage IIIA lung cancer encountered unexpectedly at surgery. However, using neoadjuvant therapy followed by surgery for known stage IIIA lung cancer as a routine therapeutic option is not supported by current published randomized trials. Combination chemoradiotherapy, especially delivered concurrently, is still the preferred treatment for prospectively recognized stage IIIA lung cancer with all degrees of mediastinal lymph node involvement. Current and future trials may modify these recommendations. Conclusions: Multimodality therapy of some type appears to be preferable in all subsets of stage IIIA patients. However, because of the relative lack of consistent randomized trial data in this subset, the following evidence-based treatment guidelines lack compelling evidence in most scenarios.

UR - http://www.scopus.com/inward/record.url?scp=34848903332&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34848903332&partnerID=8YFLogxK

U2 - 10.1378/chest.07-1379

DO - 10.1378/chest.07-1379

M3 - Article

C2 - 17873172

AN - SCOPUS:34848903332

VL - 132

SP - 243S-265S

JO - Chest

JF - Chest

SN - 0012-3692

IS - 3 SUPPL.

ER -